In contrast, there was high concordance between FdCyd-associated changes in tumor CDKN2A hypomethylation and p16 expression in CK+ CTCs among the 6 patients evaluable for both, with 5 of 6 patients exhibiting both increased tumor CDKN2A hypomethylation and CK+ CTC p16 re-expression and the remaining patient exhibiting no increases in either p16 measurement. This evidence concerns the gene CDKN2A and neoplasm.